| 注册
首页|期刊导航|中国肺癌杂志|CD133作为肺癌干细胞标记物的应用及其局限性

CD133作为肺癌干细胞标记物的应用及其局限性

陈寅

中国肺癌杂志2011,Vol.14Issue(10):825-829,5.
中国肺癌杂志2011,Vol.14Issue(10):825-829,5.DOI:10.3779/j.issn.1009-3419.2011.10.10

CD133作为肺癌干细胞标记物的应用及其局限性

The Utilization and Limitation of CD133 Epitopes in Lung Cancer Stem Cells Research

陈寅1

作者信息

  • 1. 200092,上海,上海交通大学医学院附属新华医院心胸外科
  • 折叠

摘要

Abstract

Lung cancer is one of the most common tumor, which lacks of effective clinical treatment to lead to de-sirable prognosis. According to cancer stem cell hypothesis, lung cancer stem cells are considered to be responsible for carcino-genesis, development, metastasis, recurrence, invasion, resistance to chemotherapy and radiotherapy of lung cancer. In recent years, more and more institutes used glycosylated CD 133 epitopes to define, isolate, purify lung cancer stem cells. However, along with deeply research, the application of CD 133 epitopes in lung cancer stem cell research is questioned. The utilization and limitation of CD 133 epitopes in lung cancer stem cells research for the past few years is summaried in this review.

关键词

干细胞/肺肿瘤/CD133

Key words

Stem cells/ Lung neoplasms/ CD133

分类

医药卫生

引用本文复制引用

陈寅..CD133作为肺癌干细胞标记物的应用及其局限性[J].中国肺癌杂志,2011,14(10):825-829,5.

中国肺癌杂志

OA北大核心CSTPCDMEDLINE

1009-3419

访问量0
|
下载量0
段落导航相关论文